Genmab — Oktober 2018
-
Johnson & Johnson Reports 2018 Third-Quarter Results:
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $20.3 billion for the third quarter of 2018, an increase of 3.6% as compared to the...
(www.prnewswire.com)
-
Av for satan
-
amen for helvede - der er givet en massiv kreditnota RoW
-
væksten var egentlig 16% RoW, men viser en negativ vækst på omkring 15% pga one time adjustment
-
kommunikation fra JJ og GEN nærmer sig det kriminelle
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind